2 weeks Ago By Defense World Staff
Invivyd ( NASDAQ:IVVD – Free Report ) had its price target decreased by HC Wainwright from $15.00 to $10.00 in a research report sent to investors on Wednesday, Benzinga reports.
HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.
63) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.
05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.
15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.
Separately, EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Get Our Latest Stock Analysis on Invivyd Invivyd Stock Performance Hedge Funds Weigh In On Invivyd Several hedge funds have recently made changes to their positions in the company.
Proficio Capital Partners LLC purchased a new stake in Invivyd during the 3rd quarter valued at about $27,000. XTX Topco Ltd boosted its position in Invivyd by 68.1% in the second quarter.
XTX Topco Ltd now owns 37,938 shares of the company’s stock valued at $42,000 after buying an additional 15,376 shares during the last quarter. SG Americas Securities LLC increased its holdings in Invivyd by 198.6% in the 2nd quarter.
SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares during the period. Cornercap Investment Counsel Inc. purchased a new position in Invivyd during the 2nd quarter worth approximately $86,000.
Finally, Rhumbline Advisers raised its position in Invivyd by 4,434.1% during the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after buying an additional 82,164 shares during the last quarter.
70.36% of the stock is owned by institutional investors and hedge funds. Invivyd Company Profile ( Get Free Report ) Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Recommended Stories Five stocks we like better than Invivyd Top Stocks Investing in 5G Technology Vertiv’s Cool Tech Makes Its Stock Red-Hot 3 Fintech Stocks With Good 2021 Prospects MarketBeat Week in Review – 11/18 – 11/22 Trading Halts Explained 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter .
.
